FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2189971331> ?p ?o ?g. }

• W2189971331 endingPage "405" @default.
• W2189971331 startingPage "405" @default.
• W2189971331 abstract "The main high-penetrance melanoma susceptibility gene is CDKN2A, encoding p16INK4A and p14ARF. The gene MITF variant p.E318K also predisposes to melanoma and renal cell carcinoma. To date, the prevalence of MITF p.E318K and its clinical and phenotypical implications has not been previously assessed in a single cohort of Spanish patients with melanoma or in p16INK4A mutation carriers.To evaluate the prevalence of MITF p.E318K in Spanish patients with melanoma and assess the association with clinical and phenotypic features.A hospital-based, case-control study was conducted at the Melanoma Unit of Hospital Clinic of Barcelona, with MITF p.E318K genotyped in all patients using TaqMan probes. We included 531 patients: 271 patients with multiple primary melanoma (MPM) without mutations affecting p16INK4A (wild-type p16INK4A); 191 probands from melanoma-prone families with a single melanoma diagnosis and without mutations affecting p16INK4A, and 69 probands from different families carrying CDKN2A mutations affecting p16INK4A. A population-based series of 499 age- and sex-matched cancer-free individuals from the Spanish National Bank of DNA were included as controls. Patients were recruited between January 1, 1992, and June 30, 2014; data analysis was conducted from September 1 to November 30, 2014.The genetic results of the MITF p.E318K variant were correlated with clinical and phenotypic features.Among the 531 patients, the prevalence of the MITF p.E318K variant was calculated among the different subsets of patients included and was 1.9% (9 of 462) in all melanoma patients with wild-type p16INK4A, 2.6% (7 of 271) in those with MPM, and 2.9% (2 of 69) in the probands of families with p16INK4A mutations. With results reported as odds ratio (95% CI), the MITF p.E318K was associated with an increased melanoma risk (3.3 [1.43-7.43]; P < .01), especially in MPM (4.5 [1.83-11.01]; P < .01) and high nevi count (>200 nevi) (8.4 [2.14-33.19]; P < .01). Two fast-growing melanomas were detected among 2 MITF p.E318K carriers during dermatologic digital follow-up.In addition to melanoma risk, MITF p.E318K is associated with a high nevi count and could play a role in fast-growing melanomas. Testing for MITF p.E318K should not exclude patients with known mutations in p16INK4A. Strict dermatologic surveillance, periodic self-examination, and renal cell carcinoma surveillance should be encouraged in this context." @default.
• W2189971331 created "2016-06-24" @default.
• W2189971331 creator A5008551451 @default.
• W2189971331 creator A5036932434 @default.
• W2189971331 creator A5037334300 @default.
• W2189971331 creator A5037571989 @default.
• W2189971331 creator A5058542952 @default.
• W2189971331 creator A5060937087 @default.
• W2189971331 creator A5065966632 @default.
• W2189971331 creator A5071369693 @default.
• W2189971331 creator A5083730567 @default.
• W2189971331 creator A5091612621 @default.
• W2189971331 date "2016-04-01" @default.
• W2189971331 modified "2023-10-18" @default.
• W2189971331 title "Prevalence of<i>MITF</i>p.E318K in Patients With Melanoma Independent of the Presence of<i>CDKN2A</i>Causative Mutations" @default.
• W2189971331 cites W1551338341 @default.
• W2189971331 cites W1982416785 @default.
• W2189971331 cites W1982635732 @default.
• W2189971331 cites W1983079102 @default.
• W2189971331 cites W1985550131 @default.
• W2189971331 cites W1986588122 @default.
• W2189971331 cites W1992258727 @default.
• W2189971331 cites W2003659253 @default.
• W2189971331 cites W2004646359 @default.
• W2189971331 cites W2009766515 @default.
• W2189971331 cites W2021253713 @default.
• W2189971331 cites W2024992394 @default.
• W2189971331 cites W2030257173 @default.
• W2189971331 cites W2034013771 @default.
• W2189971331 cites W2035889318 @default.
• W2189971331 cites W2046558035 @default.
• W2189971331 cites W2048001425 @default.
• W2189971331 cites W2060619528 @default.
• W2189971331 cites W2061734521 @default.
• W2189971331 cites W2062532725 @default.
• W2189971331 cites W2064977866 @default.
• W2189971331 cites W2075587871 @default.
• W2189971331 cites W2080757527 @default.
• W2189971331 cites W2081552231 @default.
• W2189971331 cites W2082633012 @default.
• W2189971331 cites W2085610925 @default.
• W2189971331 cites W2089699649 @default.
• W2189971331 cites W2097069908 @default.
• W2189971331 cites W2099911321 @default.
• W2189971331 cites W2106621675 @default.
• W2189971331 cites W2106699470 @default.
• W2189971331 cites W2115763961 @default.
• W2189971331 cites W2131906164 @default.
• W2189971331 cites W2138797163 @default.
• W2189971331 cites W2153938645 @default.
• W2189971331 cites W2156222959 @default.
• W2189971331 cites W2162066233 @default.
• W2189971331 cites W2165951266 @default.
• W2189971331 cites W2167418220 @default.
• W2189971331 doi "https://doi.org/10.1001/jamadermatol.2015.4356" @default.
• W2189971331 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26650189" @default.
• W2189971331 hasPublicationYear "2016" @default.
• W2189971331 type Work @default.
• W2189971331 sameAs 2189971331 @default.
• W2189971331 citedByCount "40" @default.
• W2189971331 countsByYear W21899713312016 @default.
• W2189971331 countsByYear W21899713312017 @default.
• W2189971331 countsByYear W21899713312018 @default.
• W2189971331 countsByYear W21899713312019 @default.
• W2189971331 countsByYear W21899713312020 @default.
• W2189971331 countsByYear W21899713312021 @default.
• W2189971331 countsByYear W21899713312022 @default.
• W2189971331 countsByYear W21899713312023 @default.
• W2189971331 crossrefType "journal-article" @default.
• W2189971331 hasAuthorship W2189971331A5008551451 @default.
• W2189971331 hasAuthorship W2189971331A5036932434 @default.
• W2189971331 hasAuthorship W2189971331A5037334300 @default.
• W2189971331 hasAuthorship W2189971331A5037571989 @default.
• W2189971331 hasAuthorship W2189971331A5058542952 @default.
• W2189971331 hasAuthorship W2189971331A5060937087 @default.
• W2189971331 hasAuthorship W2189971331A5065966632 @default.
• W2189971331 hasAuthorship W2189971331A5071369693 @default.
• W2189971331 hasAuthorship W2189971331A5083730567 @default.
• W2189971331 hasAuthorship W2189971331A5091612621 @default.
• W2189971331 hasBestOaLocation W21899713311 @default.
• W2189971331 hasConcept C104317684 @default.
• W2189971331 hasConcept C121608353 @default.
• W2189971331 hasConcept C126322002 @default.
• W2189971331 hasConcept C127716648 @default.
• W2189971331 hasConcept C143998085 @default.
• W2189971331 hasConcept C177504595 @default.
• W2189971331 hasConcept C188997412 @default.
• W2189971331 hasConcept C200544954 @default.
• W2189971331 hasConcept C2777658100 @default.
• W2189971331 hasConcept C2780265364 @default.
• W2189971331 hasConcept C2908647359 @default.
• W2189971331 hasConcept C501734568 @default.
• W2189971331 hasConcept C502942594 @default.
• W2189971331 hasConcept C54355233 @default.
• W2189971331 hasConcept C71924100 @default.
• W2189971331 hasConcept C72563966 @default.
• W2189971331 hasConcept C86339819 @default.
• W2189971331 hasConcept C86803240 @default.

• next